LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
Iona Everson | September 19, 2025 | News story | Medical Communications, Research and Development | LGC Group, biotech, life sciences, pharma
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of Excellence in Ontario, Canada after a CAD $100m investment.
The 203,000 ft² (17,200 m²) facility will expand Toronto Research Chemicals’ (TRC) capacity to serve pharmaceutical, biotechnology and life sciences customers worldwide.
Founded more than 40 years ago and acquired by LGC in 2019, TRC works to synthesise complex organic molecules. These compounds underpin global drug discovery pipelines, diagnostic development, forensic testing, food and environmental safety and industrial innovation.
“This $100m investment is about building capacity at scale,” said Joydeep Goswami, CEO of LGC Group. “Our scientists will help tackle challenges like precision medicine, PFAS detection, and sustainable chemistry, while supplying solutions that protect health, food and the environment.”
Products manufactured at the new facility will be shipped to more than 170 countries, enabling research in areas such as cancer, infectious disease, mental health and environmental safety.
“TRC’s science may start in our labs, but its impact is felt worldwide – in hospitals, communities, and industries that depend on reliable answers,” said Bruno Rossi, EVP and General Manager, LGC Standards. “With this new facility, we’re building on 40 years of expertise to deliver faster, broader, and more sustainable innovation for scientists everywhere.”
The Centre’s opening ceremony included a symposium on PFAS (per- and polyfluoroalkyl substances), widely known as ‘forever chemicals’ because they remain in the environment and accumulate in people and wildlife.
Linked to risks for human health and ecosystems, PFAS represent one of today’s most urgent environmental challenges, and the symposium brought together experts from academia and industry to explore solutions and support PFAS detection, monitoring and regulation worldwide.
This article featured in: October 2025 – The Pharmafile Brief
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
Sapio Sciences and Ultima Genomics form multi-omics research partnership
Sapio Sciences and Ultima Genomics have formed a strategic partnership to accelerate genomics research. The …
